Search - tctmd.com

Displaying 381 - 400 of 431

Sort: Relevancy | Date

News Opinion Editor's Corner

TCTMD’s Top 10 Most Popular Stories for January 2016

Shelley Wood

February 01, 2016

News Features

PCSK9 Inhibitors: Good Early Responses With Pricey Drugs, but Doctors Still Waiting on Real Data

Michael O'Riordan

January 25, 2016

News Industry News

Amgen's Repatha® (Evolocumab) Approved As First PCSK9 Inhibitor In Japan For The Treatment Of High Cholesterol

January 21, 2016

News Daily News

Year in Review: Physicians Select the Most Important News of 2015, in Interventional Cardiology and Beyond

December 23, 2015

News Daily News

他汀类药物对主动脉钙化的效果？影像学研究再次引发低密度脂蛋白在主动脉瓣疾病中作用的争论

Shelley Wood

December 16, 2015

News Daily News

¿Estatinas para el Manejo de la Calcificación Aórtica? Un Estudio de Imágenes Debate sobre el Papel de las LBD en la Enfermedad de la Válvula Aórtica

Shelley Wood

December 16, 2015

News Daily News

Statins for Aortic Calcification? Imaging Study Reopens Debate Over LDL’s Role in Aortic Valve Disease

Shelley Wood

December 16, 2015

News Conference News AHA 2015

Degree of LDL Cholesterol-Lowering on High-Intensity Rosuvastatin Determines Clinical Impact

Todd Neale

November 12, 2015

News Conference News AHA 2015

AHA 2015 Promises Appropriate PCI, Ticagrelor Tolerance, Outcomes With IVUS, and More

Shelley Wood

November 05, 2015

Presentation TCT 2015

Statin Pretreatment Prior to PCI: Are the Effects Real?

Presenter: Frederick Feit, C. Michael Gibson, Germano Di Sciascio

October 15, 2015

Presentation TCT 2015

Cilostazol: When to Consider (and Is the Data Robust?)

Presenter: Frederick Feit, C. Michael Gibson

October 15, 2015

Presentation TCT 2015

The PCSK9 Inhibitor Revolution

Presenter: Frederick Feit, C. Michael Gibson, Norman E. Lepor

October 15, 2015

Presentation TCT 2015

Hyperlipidemic Therapy: From Statins to PCSK9 Inhibitors

Presenter: George D. Dangas, Paul A. Gurbel, Joshua W. Knowles

October 13, 2015

Presentation TCT 2015

Adjuvant Pharmacotherapy With Ranolazine In Patients With Ischemic Heart Disease

Presenter: Bernard J. Gersh, Stephen D. Wiviott, Giora Weisz

October 13, 2015

Presentation TCT 2015

Non-LDL Lowering Agents: Trials and Tribulations of HDL, Triglycerides, and Lp-PLA2 What Hasnt Worked, and Why?

Presenter: Bernard J. Gersh, Stephen D. Wiviott

October 13, 2015

Presentation TCT 2015

PCSK9: Effects on LDL and Emerging Data on Cardiovascular Events

Presenter: Bernard J. Gersh, Stephen D. Wiviott, Evan A. Stein

October 13, 2015

Presentation TCT 2015

Optimal Medical Therapy After PCI: What Is Optimal, and What Is Realistic?

Presenter: Bernard J. Gersh, Stephen D. Wiviott, David J. Maron

October 13, 2015

Presentation TCT 2015

Will PCSK9 Inhibitors Transform the Natural History of Atherosclerosis?

Presenter: Gregg W. Stone, Renu Virmani, Philippe Gabriel Steg

October 12, 2015

News Industry News

Regeneron and Sanofi Announce Approval of Praluent® (alirocumab) for the Treatment of Hypercholesterolemia in the European Union

September 28, 2015

News Industry News

Amgen Submits Application To FDA For New Delivery Option For Monthly Administration Of Repatha™ (Evolocumab)

September 11, 2015

Advertisement

TCTMD’s Top 10 Most Popular Stories for January 2016

PCSK9 Inhibitors: Good Early Responses With Pricey Drugs, but Doctors Still Waiting on Real Data

Amgen's Repatha® (Evolocumab) Approved As First PCSK9 Inhibitor In Japan For The Treatment Of High Cholesterol

Year in Review: Physicians Select the Most Important News of 2015, in Interventional Cardiology and Beyond

他汀类药物对主动脉钙化的效果？影像学研究再次引发低密度脂蛋白在主动脉瓣疾病中作用的争论

¿Estatinas para el Manejo de la Calcificación Aórtica? Un Estudio de Imágenes Debate sobre el Papel de las LBD en la Enfermedad de la Válvula Aórtica

Statins for Aortic Calcification? Imaging Study Reopens Debate Over LDL’s Role in Aortic Valve Disease

Degree of LDL Cholesterol-Lowering on High-Intensity Rosuvastatin Determines Clinical Impact

AHA 2015 Promises Appropriate PCI, Ticagrelor Tolerance, Outcomes With IVUS, and More

Statin Pretreatment Prior to PCI: Are the Effects Real?

Cilostazol: When to Consider (and Is the Data Robust?)

The PCSK9 Inhibitor Revolution

Hyperlipidemic Therapy: From Statins to PCSK9 Inhibitors

Adjuvant Pharmacotherapy With Ranolazine In Patients With Ischemic Heart Disease

Non-LDL Lowering Agents: Trials and Tribulations of HDL, Triglycerides, and Lp-PLA2 What Hasnt Worked, and Why?

PCSK9: Effects on LDL and Emerging Data on Cardiovascular Events

Optimal Medical Therapy After PCI: What Is Optimal, and What Is Realistic?

Will PCSK9 Inhibitors Transform the Natural History of Atherosclerosis?

Regeneron and Sanofi Announce Approval of Praluent® (alirocumab) for the Treatment of Hypercholesterolemia in the European Union

Amgen Submits Application To FDA For New Delivery Option For Monthly Administration Of Repatha™ (Evolocumab)

Advertisement

Advertisement

Sign In

Forgot Your Password?

Search TCTMD

CME TITLE

Sign up for our newsletter

Search TCTMD

Submit an Event

Become a PREMIUM MEMBER or LOG IN to view exclusive content

REGISTER for free or LOG IN to view this content